<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Gene test interpretation: &lt;i&gt;BRCA1&lt;/i&gt; and &lt;i&gt;BRCA2&lt;/i&gt;</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Gene test interpretation: <i>BRCA1</i> and <i>BRCA2</i></h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Gene test interpretation: <i>BRCA1</i> and <i>BRCA2</i></div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Beth N Peshkin, MS, CGC</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Claudine Isaacs, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Harold J Burstein, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anne Slavotinek, MBBS, PhD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 20, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1376432669"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>This monograph summarizes interpretation of germline testing of<em> BRCA1</em> and <em>BRCA2 </em>genes. It does not discuss indications for testing and is not intended to replace clinical judgment in the decision to test or the care of the tested individual. These subjects are discussed separately [<a href="#rid1">1</a>]. (See <a class="local">'UpToDate topics'</a> below.)</p><p class="headingAnchor" id="H1216539630"><span class="h1">OVERVIEW</span></p><p class="headingAnchor" id="H2528598450"><span class="h2">How to read the report</span><span class="headingEndMark"> — </span>The checklist summarizes an approach to reviewing the report  (<a class="graphic graphic_table graphicRef122437" href="/z/d/graphic/122437.html" rel="external">table 1</a>). Considerations include extent of testing, accuracy of variant identification, and interpretation:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extent of testing</strong> – Most laboratories perform comprehensive sequencing of <em>BRCA1</em> and <em>BRCA2 </em>genes; however, it is important to determine whether the entire gene, coding regions, or selected variants were evaluated.</p><p></p><p class="bulletIndent1">Comprehensive testing can identify thousands of variants, including many that are clearly established as pathogenic or benign. Most individuals should be offered comprehensive sequencing <em>of BRCA1</em> a<em>nd BRCA2 </em>regardless of their familial variant or ancestry because pathogenic variants are seen in the general population, and compound heterozygotes have been identified unexpectedly.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Accuracy</strong> – Laboratories are certified according to the Clinical Laboratory Improvement Amendments (CLIA). If results were obtained by direct-to-consumer testing or research, testing should be repeated, possibly with additional gene tests, in a CLIA-certified laboratory or other nationally certified laboratory. This is particularly true if test results would impact clinical care of the patient and/or relatives, such as a pathogenic variant in a gene with known clinical significance that is potentially clinically actionable, or a negative finding in an individual with a suspected cancer syndrome.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interpretation</strong> – Pathogenicity is classified based on established criteria. The interpretation may require updating, particularly for a variant of uncertain significance (VUS). (See <a class="local">'Classification of variants'</a> below.)</p><p></p><p>The table provides a glossary of genetic testing terms  (<a class="graphic graphic_table graphicRef122429" href="/z/d/graphic/122429.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H1444265617"><span class="h2">Classification of variants</span><span class="headingEndMark"> — </span>The pathogenicity of each variant is classified by the laboratory into one of five categories  (<a class="graphic graphic_table graphicRef122646" href="/z/d/graphic/122646.html" rel="external">table 3</a>), using information available at the time [<a href="#rid2">2</a>]. The classification for many variants continues to be updated, especially for VUS, as more evidence from research becomes available [<a href="#rid3">3</a>]. The uncertainty reflects the available data on the role of the variant rather than the accuracy of genotyping.</p><p>If there is concern about the classification, such as for a VUS or low-penetrance variant, obtain an updated interpretation periodically (eg, annually) or when clinical management decisions might be altered. This can be done by checking a database such as <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fclinvar%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4trzGy12ipcVcj41059JRLkL3&amp;TOPIC_ID=121802" target="_blank">ClinVar</a>, contacting the laboratory, or consulting a specialist, clinical geneticist, or genetic counselor (see <a class="local">'Locating a genetics expert'</a> below); there is no gold standard approach. </p><p>Some laboratories routinely provide updates; others provide more information only when requested. Many VUS are reclassified as benign.</p><p>Likely benign and benign variants are not routinely reported (or are reported as negative); however, this information may be noted when a VUS is downgraded.</p><p class="headingAnchor" id="H1876887210"><span class="h2">Disease associations</span><span class="headingEndMark"> — </span>Pathogenic and likely pathogenic variants in <em>BRCA1</em> and <em>BRCA2</em> are associated with increased risk for several cancers  (<a class="graphic graphic_table graphicRef99937" href="/z/d/graphic/99937.html" rel="external">table 4</a>). This is traditionally referred to as hereditary breast and ovarian cancer (HBOC) syndrome, although there are other increased risks including prostate cancer and pancreatic cancer [<a href="#rid4">4</a>]. </p><p><em>BRCA1-</em> or <em>BRCA2</em>-associated HBOC syndrome is autosomal dominant with incomplete penetrance  (<a class="graphic graphic_table graphicRef122429" href="/z/d/graphic/122429.html" rel="external">table 2</a>). A pathogenic variant in either gene inherited from one parent increases the risk for the associated cancers; however, not all individuals with a variant will develop cancer. The tested individual's risk increases with age. Disease penetrance can also be modified by family history, other gene variants, and acquired risk factors. (See  <a class="medical medical_review" href="/z/d/html/792.html" rel="external">"Factors that modify breast cancer risk in women"</a>.)</p><p>Rarely, biallelic pathogenic variants in <em>BRCA2</em> are associated with Fanconi anemia (FA), and biallelic pathogenic variants in <em>BRCA1 </em>are associated with a FA-like syndrome. (See  <a class="medical medical_review" href="/z/d/html/109795.html" rel="external">"Clinical manifestations and diagnosis of Fanconi anemia", section on 'Genetics'</a>.)</p><p class="headingAnchor" id="H3565817883"><span class="h1">PEOPLE WITHOUT CANCER</span></p><p class="headingAnchor" id="H645558902"><span class="h2">Implications of a pathogenic or likely pathogenic variant</span><span class="headingEndMark"> — </span>We treat pathogenic and likely pathogenic variants in <em>BRCA1</em> and <em>BRCA2</em> the same for counseling and risk management, regardless of the reason for testing and family history. </p><p>Discussion includes the cancer risks  (<a class="graphic graphic_table graphicRef99937" href="/z/d/graphic/99937.html" rel="external">table 4</a>), possible interventions for surveillance or risk reduction  (<a class="graphic graphic_table graphicRef121904" href="/z/d/graphic/121904.html" rel="external">table 5</a>), reproductive counseling, and implications for at-risk relatives (see <a class="local">'Other considerations'</a> below). Risks depend on the person's age. </p><p>Counseling may require additional visits or referral to a specialist; management decisions can be deferred until questions have been answered.</p><p>We adhere to the National Comprehensive Cancer Network (NCCN) recommendations for surveillance and risk reduction [<a href="#rid5">5</a>]. Cancer type and age of onset in family members may inform screening (earlier screening if a relative has earlier onset). </p><p>Several surveillance and risk reduction strategies exist  (<a class="graphic graphic_table graphicRef121904" href="/z/d/graphic/121904.html" rel="external">table 5</a>). Use depends on the patient's age, values and preferences, and, for females, desire for childbearing  (<a class="graphic graphic_algorithm graphicRef122533" href="/z/d/graphic/122533.html" rel="external">algorithm 1</a>). </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Breast cancer</strong>:</p><p></p><p class="bulletIndent1">Females: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Increased surveillance:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Breast awareness and self-examination starting at age 18.</p><p class="bulletIndent3"><span class="glyph">-</span>Clinical breast examination every 6 to 12 months starting at age 25.</p><p class="bulletIndent3"><span class="glyph">-</span>Annual magnetic resonance imaging (MRI) with contrast starting at age 25 to 29 (or individualized based on family history).</p><p class="bulletIndent3"><span class="glyph">-</span>Annual mammography with consideration of tomosynthesis starting at age 30.</p><p class="bulletIndent3"><span class="glyph">-</span>Individualized management after age 75.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Discussion of risk-reducing bilateral mastectomy, with shared decision-making [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hormonal chemoprevention (<a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> or an aromatase inhibitor) may be offered if risk-reducing mastectomy was not performed; however, efficacy data are very limited.</p><p></p><p class="bulletIndent1">Males:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Breast self-examination and annual clinical breast examination starting at age 35.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Consider annual mammography, especially those with a pathogenic or likely pathogenic variant in <em>BRCA2</em>, starting at age 50 or 10 years before the earliest known male breast cancer in the family, whichever comes first. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ovarian and other gynecologic cancers</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Recommendation for risk-reducing bilateral salpingo-oophorectomy (rrBSO)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Generally at age 35 to 40 for <em>BRCA1</em> carriers</p><p class="bulletIndent3"><span class="glyph">-</span>At age 40 to 45 for <em>BRCA2</em> carriers</p><p class="bulletIndent3"><span class="glyph">-</span>Earlier if indicated based on age at ovarian cancer diagnosis in a relative</p><p></p><p class="bulletIndent2">Females are encouraged to complete childbearing by these ages; otherwise, surgery may be performed after childbearing is complete [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/z/d/html/758.html" rel="external">"Cancer risks and management of BRCA1/2 carriers without cancer", section on 'Risk-reducing surgery'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Consideration for transvaginal ultrasound and CA-125 for females who do not elect rrBSO, with a discussion of the uncertain benefits of this approach.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Discussion of the risks and benefits of hysterectomy at the time of rrBSO [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Discussion of hormone therapy for menopausal symptoms and possibly other health risks associated with early menopause.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prostate cancer</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For <em>BRCA2</em> carriers, prostate cancer surveillance starting at age 40, including prostate-specific antigen (PSA) and digital rectal examination. For <em>BRCA1</em> carriers, discussion of the risks and benefits of prostate cancer screening starting at age 40. (See  <a class="medical medical_review" href="/z/d/html/112282.html" rel="external">"Genetic risk factors for prostate cancer", section on 'Screening implications of increased genetic risk'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pancreatic cancer</strong>: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Periodic screening for pancreatic cancer is appropriate for those with a family history of pancreatic cancer; usually includes contrast-enhanced magnetic resonance imaging (MRI)/magnetic resonance cholangiopancreatography (MRCP) and/or endoscopic ultrasound. (See  <a class="medical medical_review" href="/z/d/html/83943.html" rel="external">"Familial risk factors for pancreatic cancer and screening of high-risk patients"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Melanoma</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Consideration of annual full body skin examinations. For those with a pathogenic or likely pathogenic variant in <em>BRCA2</em>, notification of the eye care provider about the possible increased risk of ocular melanoma. (See  <a class="medical medical_review" href="/z/d/html/758.html" rel="external">"Cancer risks and management of BRCA1/2 carriers without cancer", section on 'Screening for other cancers'</a>.)</p><p></p><p class="headingAnchor" id="H1355155794"><span class="h2">Implications of a negative test</span><span class="headingEndMark"> — </span>Negative testing means no pathogenic variants were identified  (<a class="graphic graphic_algorithm graphicRef122533" href="/z/d/graphic/122533.html" rel="external">algorithm 1</a>). However, some tests may be inconclusive or may not cover all possible variants. </p><p class="bulletIndent1"><span class="glyph">●</span>Once a pathogenic variant is identified in a relative and the tested individual is demonstrated not to have that variant, they usually can be reassured that they are not at high risk for associated cancers, with the caveats above. (See <a class="local">'How to read the report'</a> above.)</p><p></p><p class="bulletIndent1">However, an individualized assessment is important, to consider factors such as the presence of non-<em>BRCA1/2</em>-associated cancers on the side of the family with the pathogenic variant, cancer history on the side of the family without the variant, as well as other personal cancer risk factors. </p><p></p><p class="bulletIndent1">For some individuals, testing with a multi-gene cancer panel is recommended rather than testing only for the familial varian<em>t, BRCA1/2</em> only, or only the Ashkenazi Jewish founder pathogenic variants <em>in BRCA1/</em>2.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If a pathogenic variant in a family has not been identified and genetic testing is negative, additional risk factors (genetic or acquired) may be present. If there is a strong suspicion of a familial cancer syndrome, such individuals, as well as those who do not have documentation of a familial variant, should undergo comprehensive testing (with a multi-gene cancer panel). Surveillance and risk reduction recommendations are based on personal risk factors and family history. Referral may be helpful to determine optimal testing if family history is suggestive of a hereditary cancer syndrome. (See <a class="local">'Locating a genetics expert'</a> below.)</p><p></p><p class="headingAnchor" id="H3359372904"><span class="h2">Implications of a VUS</span><span class="headingEndMark"> — </span>Individuals with a variant of uncertain significance (VUS) should not be managed as though they have a pathogenic or likely pathogenic variant. Management should be based on their personal and family history  (<a class="graphic graphic_algorithm graphicRef122533" href="/z/d/graphic/122533.html" rel="external">algorithm 1</a>).</p><p>The testing laboratory or other resource should be consulted periodically for updates in the classification (eg, annually). (See <a class="local">'Classification of variants'</a> above.)</p><p class="headingAnchor" id="H4278500151"><span class="h1">PEOPLE WITH CANCER</span><span class="headingEndMark"> — </span>Genetic test results should be discussed with the oncologist or surgeon; referral to a specialist in hereditary breast and ovarian cancer may be appropriate. Implications may include:</p><p class="bulletIndent1"><span class="glyph">●</span>More extensive breast cancer surgery (bilateral mastectomy to reduce the risk of a second primary breast cancer).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Incorporation of a poly-ADP-ribose polymerase (PARP) inhibitor for several different cancer types (eg, metastatic breast, prostate, pancreatic, and ovarian cancer).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Decisions about active surveillance versus local treatment for early-stage prostate cancer, given that <em>BRCA1/2-</em>associated prostate cancers tend to be more aggressive and have a poorer prognosis than those in the general population. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Additional surveillance and risk reduction. (See <a class="local">'Implications of a pathogenic or likely pathogenic variant'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Genetic counseling and testing of adult relatives is recommended. (See <a class="local">'Other considerations'</a> below.)</p><p></p><p>For individuals with a negative test or a variant of uncertain significance (VUS) for whom there are reasons to be concerned about a genetic cause, additional genetic testing may be appropriate and can be discussed with a genetic counselor, the primary oncologist, or other specialists. (See <a class="local">'Locating a genetics expert'</a> below.)</p><p class="headingAnchor" id="H2500447871"><span class="h1">OTHER CONSIDERATIONS</span></p><p class="headingAnchor" id="H3040693472"><span class="h2">Reproductive counseling</span><span class="headingEndMark"> — </span>Preconception counseling is appropriate for individuals with a pathogenic or likely pathogenic variant in <em>BRCA1</em> or <em>BRCA2</em> who are considering childbearing.</p><p>Some may elect to use donor gametes or in vitro fertilization (IVF) with preimplantation genetic testing (PGT). Some may elect prenatal diagnosis. (See  <a class="medical medical_review" href="/z/d/html/6783.html" rel="external">"Preimplantation genetic testing", section on 'Patients known to be at increased risk of offspring with a specific medically actionable condition'</a>.) </p><p class="headingAnchor" id="H1610925974"><span class="h2">At-risk relatives</span><span class="headingEndMark"> — </span>Individuals with a pathogenic variant or likely pathogenic variant should inform their at-risk relatives about the importance of genetic counseling and possible testing.</p><p class="bulletIndent1"><span class="glyph">●</span>The risk of inheriting the variant is 50 percent for first-degree relatives (siblings and children). Other at-risk relatives may include aunts, uncles, nieces, nephews, and cousins. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Usually the variant segregates on the side of the family with a history of associated cancer(s); however, if possible, it is recommended to test a parent or other relative with cancer to determine the at-risk side of the family.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>BRCA1 and BRAC2-</em>associated cancers rarely occur before adulthood. Genetic testing can be deferred until age ≥18 years to allow autonomous decision-making and informed consent. (See  <a class="medical medical_review" href="/z/d/html/2901.html" rel="external">"Genetic testing", section on 'Ethical, legal, and psychosocial issues'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Resources are listed below. (See <a class="local">'Family communication'</a> below.)</p><p></p><p class="headingAnchor" id="H2547325145"><span class="h1">RESOURCES</span></p><p class="headingAnchor" id="H2307191863"><span class="h2">UpToDate topics</span></p><p class="bulletIndent1"><span class="glyph">●</span>Cancer risks – (See  <a class="medical medical_review" href="/z/d/html/758.html" rel="external">"Cancer risks and management of BRCA1/2 carriers without cancer"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Genetic testing – (See  <a class="medical medical_review" href="/z/d/html/753.html" rel="external">"Genetic testing and management of individuals at risk of hereditary breast and ovarian cancer syndromes"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Breast cancer – (See  <a class="medical medical_review" href="/z/d/html/792.html" rel="external">"Factors that modify breast cancer risk in women"</a> and  <a class="medical medical_review" href="/z/d/html/14227.html" rel="external">"ER/PR negative, HER2-negative (triple-negative) breast cancer"</a> and  <a class="medical medical_review" href="/z/d/html/767.html" rel="external">"Overview of the approach to metastatic breast cancer", section on 'Special considerations'</a> and  <a class="medical medical_review" href="/z/d/html/94744.html" rel="external">"Contralateral prophylactic mastectomy"</a> and  <a class="medical medical_review" href="/z/d/html/779.html" rel="external">"Breast cancer in men"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Ovarian cancer – (See  <a class="medical medical_review" href="/z/d/html/3250.html" rel="external">"Risk-reducing salpingo-oophorectomy in patients at high risk of epithelial ovarian and fallopian tube cancer"</a> and  <a class="medical medical_review" href="/z/d/html/121057.html" rel="external">"Management of ovarian cancer associated with BRCA and other genetic mutations"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Prostate cancer – (See  <a class="medical medical_review" href="/z/d/html/112282.html" rel="external">"Genetic risk factors for prostate cancer"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Pancreatic cancer – (See  <a class="medical medical_review" href="/z/d/html/83943.html" rel="external">"Familial risk factors for pancreatic cancer and screening of high-risk patients"</a>.)</p><p></p><p class="headingAnchor" id="H1680160698"><span class="h2">Family communication</span></p><p class="bulletIndent1"><span class="glyph">●</span>Facing Our Risk of Cancer Empowered (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.facingourrisk.org%2F&amp;token=8RYIFfyLhIBYEqeX7m6uPJlcl%2F6pKEzpiIQmSeLsUN0MAqXwiWEevFVkuS%2B57sZy&amp;TOPIC_ID=121802" target="_blank">FORCE</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.facingourrisk.org%2Fuploads%2FFORCE-TellingFamilies-5.5x8.5-200914-F_nobleeds.pdf&amp;token=tpMfyQJRCxIzII1YjJbEc65uA0LQFTNi3%2BI9SwB8H1Vd%2BH41brmVnG2wjW9CVnkmdGB%2BWQRPz9FBM2SqLsSBdULFmlq7rb5udWr7c9ZGu3HQ6wEjxEe1lLlwswKl8VUo&amp;TOPIC_ID=121802" target="_blank">Booklet</a> [<a href="#rid7">7</a>]</p><p class="bulletIndent2"><span class="glyph">•</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.facingourrisk.org%2Fuploads%2FSharing+Worksheet+May+2020.pdf&amp;token=8RYIFfyLhIBYEqeX7m6uPJlcl%2F6pKEzpiIQmSeLsUN3ZKGugnF15ZNb3cMY0i5ik2PEtP8jak02CLySdk2gGwu6MetmVho5%2BXAgRS%2Fu%2B%2BTs%3D&amp;TOPIC_ID=121802" target="_blank">Worksheet</a> [<a href="#rid8">8</a>]</p><p></p><p class="headingAnchor" id="H482204110"><span class="h2">Locating a genetics expert</span></p><p class="bulletIndent1"><span class="glyph">●</span>Clinical geneticists – American College of Medical Genetics and Genomics (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinics.acmg.net%2F&amp;token=nbsXe3i4qfUea5RCPRHtOdEP95SDL7NSm8b1jbZpdwjlW9H1hfmmq%2FTbAbE64qhV&amp;TOPIC_ID=121802" target="_blank">ACMG</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Genetic counselors – National Society of Genetic Counselors (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffindageneticcounselor.nsgc.org%2F&amp;token=AU2cQkyAZolWVu502Wzur%2F2gjdsB%2FYlqRYYyoKtNflwwaDFffULns7AVKZBF0Vtm&amp;TOPIC_ID=121802" target="_blank">NSGC</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>National Institutes of Health (NIH) Cancer Genetics <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cancer.gov%2Fabout-cancer%2Fcauses-prevention%2Fgenetics%2Fdirectory&amp;token=j%2Fp%2BIZfImoJgnd%2Fk4T5MAbDlZmLADFk1VrVOJqDdPzf1mGWFw3YadpFlBYSMxNKDeExYMR0QNQoNISFKbh7RPtm%2BfHLonSi2ZDCqhRzTq0w%3D&amp;TOPIC_ID=121802" target="_blank">Services Directory</a> </p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.</li><li><a class="nounderline abstract_t">Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17:405.</a></li><li><a class="nounderline abstract_t">Mighton C, Charames GS, Wang M, et al. Variant classification changes over time in BRCA1 and BRCA2. Genet Med 2019; 21:2248.</a></li><li><a class="nounderline abstract_t">Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA 2017; 317:2402.</a></li><li class="breakAll">Genetic/familial high-risk assessment: Breast, ovarian, and pancreatic, version 2.2023. NCCN clinical practice guidelines in oncology. Available at: https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf (Accessed on January 18, 2023).</li><li><a class="nounderline abstract_t">Hartmann LC, Lindor NM. The Role of Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer. N Engl J Med 2016; 374:454.</a></li><li class="breakAll">The Genes Between Us: Your guide to sharing genetic test results with relatives. Facing Our Risk of Cancer Empowered (FORCE). https://www.facingourrisk.org/uploads/FORCE-TellingFamilies-5.5x8.5-200914-F_nobleeds.pdf (Accessed on May 03, 2022).</li><li class="breakAll">Worksheet for Sharing Cancer Information with the Family. Facing Our Risk of Cancer Empowered (FORCE). Available at: https://www.facingourrisk.org/uploads/Sharing%20Worksheet%20May%202020.pdf (Accessed on May 03, 2022).</li></ol></div><div id="topicVersionRevision">Topic 121802 Version 10.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25741868" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30971832" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Variant classification changes over time in BRCA1 and BRCA2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28632866" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28632866" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26840135" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The Role of Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
